Development of Novel Approaches for the Pharmacologic Treatment of Atrial Fibrill
Development of Novel Approaches for the Pharmacologic Treatment of Atrial Fibrill
批准号:
8575543
负责人:
Charles Antzelevitch
金额:
$42.88万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-05-01 至 2014-11-30
关键词:
Action PotentialsAffectAgingAgonistAmericanArrhythmiaAtrial FibrillationCalciumCanis familiarisCellsCharacteristicsClinicComplicationCongestive Heart FailureDevelopmentDilated CardiomyopathyDrug CombinationsEffectivenessElectrophysiology (science)EpidemicGoalsHeartHeart AtriumHeart failureHeterogeneityHomeostasisHospitalizationLaboratoriesLeadLeftLeft atrial structureMedicalMedication ManagementMyocardiumPatientsPharmacologyPhasePlayPopulationPreparationPrevalencePulmonary veinsResearchResearch DesignRight atrial structureRoleSocietiesSodium ChannelSodium Channel BlockersStagingTestingTherapeuticTissuesUnited StatesVentricularVentricular ArrhythmiaVentricular Functionabstractingage relatedbaseclinically relevantdesigninnovationmortalitynovelnovel strategiesprevent
中文摘要
点击翻译按钮获取中文摘要
英文摘要
7. Project Summary Abstract
Our proposal is designed to characterize the electrical heterogeneity intrinsic to the atrial and ventricular
myocardium, to which our group has contributed significantly over the past many years. Our specific
aims are to: 1) probe differences in sodium channel and action potential characteristics of atrial vs. ventri-
cular cells isolated from the canine heart and assess how these distinctions contribute to atrial-selective so-
dium channel inhibition and suppression of atrial fibrillation by INa blockers; 2) determine to what extent the
electrical and pharmacologic heterogeneities uncovered in the canine right atrium exist in the left atrium; 3)
determine to what extent electrical and pharmacologic heterogeneities uncovered in canine right and left
atria of normal dogs differ from those of respective tissues and cells isolated from heart failure dogs (HF);
4) assess the propensity for the development of atrial fibrillation in atria isolated from heart failure dogs and
define the substrate and triggers that underlie arrhythmogenesis. 5) assess the effectiveness of different
classes of sodium channel blockers in terminating and suppressing re-induction of AF, determine to what
extent these agents are atrial-selective, and the mechanisms involved; 6) probe the basis for atrial-selective
sodium channel block responsible for the anti-AF effects of sodium channel blockers in HF dogs; and 7) as-
sess the influencee of parasympathetic agonists on the development of AF in atria isolated from normal and
heart failure dogs. The principal goals of our proposal are to probe the extent to which electrical hetero-
geneities exist between the right and left atrium and ventricles of the canine heart and examine how am-
plification of these heterogeneities contributes to the development of atrial and ventricular arrhythmias in
the normal heart as well as in structurally compromised hearts isolated from dogs with pacing-induced
dilated cardiomyopathy. The proposed project is a clinically relevant research inquiry designed to advance
our understanding of atrial arrhythmia development and approach to therapy. The central focus involving a
test of the hypothesis that atrial-selective modulation of the sodium channel can prevent AF without signifi-
cantly altering ventricular electrophysiology is innovative and exciting and has the potential to produce a pa-
radigm shift in the pharmacologic approach to therapy of AF, one of the greatest unmet medical needs
facing our society. Successful completion of the project will also identify the ionic and cellular mechanisms
that contribute to atrial selectivity, thus creating a unique platform for the development of novel therapies
that could potentially find their way to the bedside.
期刊论文(327)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1371/journal.pone.0242747
发表时间:
2020
期刊:
PloS one
影响因子:
3.7
作者:
[Di Diego JM, Patocskai B, Barajas-Martinez H, Borbáth V, Ackerman MJ, Burashnikov A, Clatot J, Li GR, Robinson VM, Hu D, Antzelevitch C]
通讯作者:
Antzelevitch C
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.
DOI:
10.1016/j.jacc.2010.08.600
发表时间:
2010-10-05
期刊:
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
影响因子:
24
作者:
[Burashnikov, Alexander, Sicouri, Serge, Di Diego, Jose M., Belardinelli, Luiz, Antzelevitch, Charles]
通讯作者:
Antzelevitch, Charles
DOI:
10.1016/j.tcm.2021.07.001
发表时间:
2022-08
期刊:
Trends in cardiovascular medicine
影响因子:
9.3
作者:
[Antzelevitch C, Di Diego JM]
通讯作者:
Di Diego JM
DOI:
10.1161/circep.111.968305
发表时间:
2012-04
期刊:
Circulation. Arrhythmia and electrophysiology
影响因子:
--
作者:
[Burashnikov A, Pourrier M, Gibson JK, Lynch JJ, Antzelevitch C]
通讯作者:
Antzelevitch C
DOI:
10.1161/circulationaha.111.054007
发表时间:
2012-01-03
期刊:
Circulation
影响因子:
37.8
作者:
[Kanter RJ, Pfeiffer R, Hu D, Barajas-Martinez H, Carboni MP, Antzelevitch C]
通讯作者:
Antzelevitch C
共 149 条
Development of a whole heart model of the J wave syndromes and novel approaches to pharmacologic management of associated life-threatening arrhythmias
-
批准号:10379445
-
项目类别:
-
资助金额:$62.95万
-
财政年份:2020
-
负责人:Charles Antzelevitch
-
依托单位:
Development of a whole heart model of the J wave syndromes and novel approaches to pharmacologic management of associated life-threatening arrhythmias
-
批准号:10650135
-
项目类别:
-
资助金额:$62.95万
-
财政年份:2020
-
负责人:Charles Antzelevitch
-
依托单位:
Development of Novel Approaches for the Pharmacologic Treatment of Atrial Fibrill
-
批准号:8021311
-
项目类别:
-
资助金额:$43.75万
-
财政年份:1993
-
负责人:Charles Antzelevitch
-
依托单位:
Development of Novel Approaches for the Pharmacologic Treatment of Atrial Fibrill
-
批准号:8204914
-
项目类别:
-
资助金额:$43.75万
-
财政年份:1993
-
负责人:Charles Antzelevitch
-
依托单位:
Electrical Heterogeneity and Cardiac Arrhythmias
-
批准号:7485653
-
项目类别:
-
资助金额:$41.48万
-
财政年份:1993
-
负责人:Charles Antzelevitch
-
依托单位:
Development of Novel Approaches for the Pharmacologic Treatment of Atrial Fibrill
-
批准号:8386985
-
项目类别:
-
资助金额:$41.65万
-
财政年份:1993
-
负责人:Charles Antzelevitch
-
依托单位:
海外基金